 Cost-Benefit Analysis of a New HEDIS Performance Measure for Pneumococcal VaccinationFaruque Ahmed, Elamin E. Elbasha, Betsy L. Thompson, Jeffrey R. Harris and Vishnu-Priya Sneller Medical Decision Making, 2002, vol. 22, issue 1_suppl, 58-66 Abstract: Objectives Measurement of the quality of care provided by managed care organizations (MCOs) has achieved national prominence, though there is controversy regarding its value. This article assesses the economic implications of a new Health Plan Employer Data and Information Set (HEDIS ® ) measure for pneumococcal vaccination. Methods A Markov decision model, with Monte Carlo simulations, was utilized to conduct a cost-benefit analysis of annual HEDIS-associated interventions, which were repeated for 5 consecutive years, in an average Medicare MCO, using a societal perspective and a 3% annual discount rate. Results Compared with the status quo, the HEDIS intervention will be cost saving 99.8% of the time, with an average net savings of $3.80 per enrollee (95% probability interval: $0.73–$6.87). Conclusions The new HEDIS measure will save societal dollars. This type of analysis is essential if performance measurement is to become a legitimate part of our health care landscape. Keywords: cost-benefit; cost-effectiveness; health maintenance organizations; intervention; managed care programs; outcomes assessment (health care); performance measures; pneumococcal vaccine; quality of health care. (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:22:y:2002:i:1_suppl:p:58-66 Access Statistics for this article More articles in Medical Decision Making |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.